Background
Phase 3 open-label, non-inferiority RCT (EINSTEIN-DVT). 3,449 patients with acute symptomatic proximal DVT without symptomatic PE. Randomized to rivaroxaban (single-drug approach) versus standard therapy (enoxaparin bridged to VKA). Rivaroxaban is an oral direct factor Xa inhibitor. Study evaluated whether a simplified single-drug oral regimen was non-inferior to standard dual-drug parenteral-to-oral transition.
Interventions and follow up
Arm A: Rivaroxaban 15 mg twice daily × 3 weeks, then 20 mg once daily for 3, 6, or 12 months (investigator choice)
Arm B: Enoxaparin ≥5 days overlapping with and until INR ≥2.0 on VKA (warfarin or acenocoumarol), continued for 3, 6, or 12 month
Primary endpoint: Recurrent VTE (symptomatic DVT or non-fatal/fatal PE) — non-inferiority margin 2.0 for upper CI of risk ratio
mFollow up: 3, 6, or 12 months per arm assignment
Arm B: Enoxaparin ≥5 days overlapping with and until INR ≥2.0 on VKA (warfarin or acenocoumarol), continued for 3, 6, or 12 month
Primary endpoint: Recurrent VTE (symptomatic DVT or non-fatal/fatal PE) — non-inferiority margin 2.0 for upper CI of risk ratio
mFollow up: 3, 6, or 12 months per arm assignment
Results
Recurrent VTE: 2.1% (rivaroxaban) vs 3.0% (enoxaparin/VKA); HR 0.68, 95% CI 0.44–1.04 — non-inferior (P<.001 for non-inferiority)
Major bleeding: 0.8% vs 1.2%; HR 0.65, 95% CI 0.33–1.30 (non-significant)
Clinically relevant non-major bleeding: 5.8% vs 8.1%
Major bleeding: 0.8% vs 1.2%; HR 0.65, 95% CI 0.33–1.30 (non-significant)
Clinically relevant non-major bleeding: 5.8% vs 8.1%
Adverse events
Main adverse events: Major or clinically relevant non-major bleeding: 8.1% vs 11.4% (rivaroxaban vs enoxaparin/VKA; P=.007). Fatal bleeding: 0.1% each arm. No significant difference in net clinical benefit. Liver enzyme elevations rare.
Conclusions
Rivaroxaban as a single-drug oral regimen was non-inferior to enoxaparin/VKA for acute DVT treatment with a favorable bleeding profile, establishing DOACs as a simplified alternative to standard parenteral bridging therapy.
Key Limitations
Key Limitations: Open-label design — blinding not feasible with different administration routes, introducing potential adjudication bias. Non-inferiority trial design; superiority not the primary objective. VKA time-in-therapeutic-range not reported. Treatment duration was investigator choice (not randomized), complicating subgroup analysis. Concurrent EINSTEIN-PE trial reported separately.
Clinical Context
Together with EINSTEIN-PE (2012), EINSTEIN-DVT established rivaroxaban as the first DOAC approved for acute VTE treatment (FDA 2012). The single-drug oral approach (no parenteral bridge needed) simplified VTE management significantly. Current guidelines (ACCP, ASH, ESC) recommend DOACs over VKA for most patients with acute VTE in the absence of contraindications such as antiphospholipid syndrome or severe renal impairment.
References